Skip to content
Back

Bernadette Liemberger, PhD

Scientific Associate

Research statement

My area of research and therefore my interests in science lie within genetics and molecular biology. I am especially interested in persuing the development of a therapy for EB patients and therefore focusing on an RNA-targeting therapy for RDEB, that makes it possible to repair a variety of COL7A1-associated mutations in patient-derived cells.

Personal interests

In my spare time I love to read all kinds of books (Crime/Thriller, Fantasy, Science Fiction, fiction) or go inline skating/cycling.

Curriculum Vitae Bernadette Liemberger

Professional Career

Since 2020
Scientific Associate
at the EB House Austria

 

Education

2020
PhD,
Natural Sciences, Paris Lodron University Salzburg
"Antisense RNA-mediated improvement of SMaRT therapy for KRT14 correction"
Research group: Univ.-Prof. Dr. Johann W. Bauer

2016
MSc
in Molecular Biology, Paris Lodron University Salzburg
"Pathological mechanisms underlying contracture formation in epidermolysis bullosa"
Research group: Univ.-Prof. Dr. Johann W. Bauer

2012
B.rer.nat.
in Molecular Biology, Paris Lodron University Salzburg

Original articles

  1. Kocher T, Bischof J, Haas SA, March OP, Liemberger B, Hainzl S, Illmer J, Hoog A, Muigg K, Binder HM, Klausegger A, Strunk D, Bauer JW, Cathomen T, Koller U. A non-viral and selection-free COL7A1 HDR approach with improved safety profile for dystrophic epidermolysis bullosa. Molecular Therapy - Nucleic Acids, 2021
  2. Ablinger M, Lettner T, Friedl N, Potocki H, Palmetzhofer T, Koller U, Illmer J, Liemberger B, Hainzl S, Klausegger A, Reisenberger M, Lambert J, Van Gele M, Desmet E, Van Maelsaeke E, Wimmer M, Zauner R, Bauer JW, Wally V. Personalized Development of Antisense Oligonucleotides for Exon Skipping Restores Type XVII Collagen Expression in Junctional Epidermolysis Bullosa. 2021;22:3326.
  3. Kocher T, March OP, Bischof J, Liemberger B, Hainzl S, Klausegger A, Hoog A, Strunk D, Bauer JW, Koller U. Predictable CRISPR/Cas9-Mediated COL7A1 Reframing for Dystrophic Epidermolysis Bullosa. J Invest Dermatol. 2020, ISSN 0022-202X
  4. Bornert O, Kocher T, Gretzmeier C, Liemberger B, Hainzl S, Koller U, Nyström A. Generation of rabbit polyclonal human and murine collagen VII monospecific antibodies: A useful tool for dystrophic epidermolysis bullosa therapy studies. Matrix Biology Plus 2019, 100017, ISSN 2590-0285
  5. Liemberger B, Piñón Hofbauer J, Wally V, Arzt C, Hainzl S, Kocher T, Murauer EM, Bauer JW, Reichelt J, Koller U. RNA Trans-Splicing Modulation via Antisense Molecule Interference. Int J Mol Sci 2018;19(3):762

Other

  1. Kocher T, March OP, Bischof J, Liemberger B, Hainzl S, Klausegger A, Hoog A, Strunk D, Bauer JW, Koller U. CRISPR-Cas9-basierte Korrekturstrategie – vorhersagbare Reparaturergebnisse. Spectrum Dermatologie 2020;04/2020:62-3.
Back to main navigation